Article
03 Feb 2021
European And Global Private Equity Health Care And Life Sciences 2020 Review And Looking Ahead To 2021
AUTHORS CONTENT
Article
04 Feb 2019
AdvaMed Releases Updated Code Of Ethics
Article
16 Jan 2019
Changes In Federal Regulation Of CBD And Other Hemp Products Will Create New Opportunities For Investment, But Regulatory Challenges Remain
Article
24 Oct 2018
CMS Issues Proposed Rule To Require Disclosure Of List Price In Direct-To-Consumer Advertising For Prescription Drugs And Biological Products
Article
19 Jan 2018
HHS Delays Compliance Date For Revised Common Rule
Article
26 Jun 2017
MedPAC Takes Anti-POD Stance In Report To Congress, Echoing An Increasingly Uniform Consensus
Article
21 Jun 2017
Compliance Strategies For Global Life Sciences Companies (Video)
Article
20 Jun 2017
Compliance Issues For Global Life Sciences Companies (Video)
Article
20 Feb 2017
Major Effects of Revised Common Rule on Regulation of Clinical Research in New York
Article
10 Feb 2017
The GDPR – Possible Impact On The Life Sciences And Healthcare Sectors
Article
21 Jan 2017
HHS Finalizes Major Changes To The Common Rule
Article
14 Nov 2016
Trumping Obamacare: Some Likely Effects Of The Election On Health Care
Article
20 Oct 2016
European Health Care Compliance Challenges (And Solutions)
Article
30 Sep 2016
Donations And Grants In China: Compliance Controls Beyond T&E
Article
04 Aug 2016
FDA Issues Final Guidance on General Wellness Products
Article
17 May 2016
Senate Finance Report Puts Another Nail In The POD Coffin
Article
11 Mar 2016
Off-Label Enforcement Developments (Vascular Solutions, Inc. Acquittal and Amarin Settlement)
Article
25 Nov 2015
HHS Grants 30-Day Extension On Comment Period For Common Rule Revisions
Article
10 Sep 2015
HHS Proposes Major Overhaul Of The Common Rule
Article
24 Jul 2015
House Passes 21st Century Cures Act: What Does It Mean For Clinical Research?